Incyte Q1 Adjusted EPS Tops Estimates by 31%, Revenue Beats by $50M; New CFO Named
Incyte reported Q1 net income of $303.3 million, or $1.47 per share, with adjusted earnings of $1.81 surpassing estimates of $1.38. Revenue of $1.27 billion exceeded forecasts of $1.22 billion, and Suketu Upadhyay was appointed as chief financial officer.
1. Q1 Financial Results
Incyte posted first-quarter net income of $303.3 million, equivalent to $1.47 per share, and reported adjusted earnings of $1.81, outperforming analysts’ forecast of $1.38. Revenue reached $1.27 billion, topping street estimates of $1.22 billion and reflecting strong demand for the company’s specialty drug portfolio.
2. CFO Appointment
Incyte named Suketu Upadhyay as chief financial officer, tasking him with oversight of financial strategy, reporting and investor relations. Upadhyay’s appointment is aimed at bolstering the company’s financial leadership as it advances its oncology and inflammation pipeline.